Health and economic impact of combining metformin with nateglinide to achieve glycemic control: Comparison of the lifetime costs of complications in the U.K

Table 4 Sensitivity analysis

		Change in Outcome		CER
Parameter	Net Cost	LYG	QALY	Cost/LYG	Cost/QALY
Base values	£2,066	0.32	0.37	£6,772	£5,609
Age (mean)
46.5 years	£2,531	0.34	0.45	£7,476	£5,589
82.5 years	£718	0.14	0.12	£5,303	£5,804
Cost of complications
+20%	£1,973	0.32	0.37	£6,213	£5,357
-20%	£2,159	0.32	0.37	£6,799	£5,861
Duration of disease before oral agent prescribed
5 years	£2,101	0.27	0.33	£7,680	£6,320
10 years	£1,971	0.31	0.35	£6,260	£5,553
Utilities
+20%	£2,066	0.32	0.36	£6,506	£5,807
-20%	£2,066	0.32	0.38	£6,506	£5,426
Race
100% Caucasian	£2,105	0.31	0.36	£6,686	£5,771
HbA1c level
HbA1c before prescription = 9.4%	£1,782	0.37	0.42	£4,784	£4,287
Metformin = 8.6%
Combination = 7.9%
HbA1c before prescription = 7.9%	£2,184	0.28	0.34	£7,904	£6,516
Metformin = 7.1%
Combination = 6.4%
HbA1c upward drift
Metformin = 1.5%; Combination = 0%	£1,478	0.54	0.65	£2,761	£2,272
Metformin = 0%; Combination = 0%	£2,307	0.28	0.31	£8,336	£7,338
HbA1c drift delay
Metformin = 0 years; Combination = 1 year	£1,987	0.35	0.41	£5,715	£4,870
Discount
Cost = 3%; Benefit = 3%	£2,420	0.26	0.30	£9,319	£8,058
Cost = 6%; Benefit = 6%	£2,066	0.18	0.21	£11,369	£9,888
Cost = 6%; Benefit = 0%	£2,066	0.39	0.46	£5,237	£4,500

ISSN: 1478-7547